NASDAQ$LGVN
Longeveron Inc-A · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2021 and provided a business update regarding ongoing clinical trials.
Longeveron Inc. reported its financial results for the first quarter ended March 31, 2021. The company's revenue was $0.4 million, and net loss was $3.1 million. Cash on hand was $24.5 million, which the company believes will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.
- Phase 1 Alzheimer’s disease clinical study results were announced in April, and the Company remains on track to initiate a Phase 2 study in the second half of the year.
- Top-line results from two recently completed US Phase 2 Aging Frailty trials are expected in the third quarter of this year.
- A Phase 2 trial of Lomecel-B infusion in mild Alzheimer’s disease subjects is planned for the second half of 2021.
- The Japanese Aging Frailty clinical trial is on track to initiate in the second half of 2021.
Headline financials
Revenue & EPS history
Longeveron · Revenue · Quarterly
$376K
Revenue by segment
Longeveron · $400K total across 1 segment · Q1 2021
- Clinical Trial Revenue$400K-76.5%100.0%
Forward guidance
The Company believes, based on the current operating plan and financial resources, that existing cash on hand will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
-5.1%
Avg return
Earnings day
-5.7%
Avg return
5 days after
+23.1%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+10.0%
Q1 2022
Best reaction
-35.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -11.0% | — | |
| Q4 2025 | -4.7% | -0.7% | +6.1% | |
| Q3 2025 | -4.3% | -7.3% | -23.1% | |
| Q1 2025 | -10.1% | -9.4% | -17.4% | |
| Q4 2024 | -9.2% | -5.3% | +2.0% | |
| Q3 2024 | -2.3% | -8.8% | -14.3% | |
| Q2 2024 | -7.5% | -11.3% | -21.8% | |
| Q1 2024 | +3.1% | -1.5% | +106.9% | |
| Q4 2023 | +0.7% | +0.0% | -39.8% | |
| Q3 2023 | -6.7% | -0.5% | +17.6% | |
| Q2 2023 | -6.5% | -12.0% | -25.8% | |
| Q1 2023 | -6.1% | -11.9% | -0.9% | |
| Q4 2022 | -15.5% | -17.5% | -25.0% | |
| Q3 2022 | +5.1% | +2.6% | -14.1% | |
| Q2 2022 | +3.9% | +1.3% | -14.5% | |
| Q1 2022 | +10.0% | +16.2% | -0.7% | |
| Q4 2021 | -14.4% | -7.1% | +37.8% | |
| Q3 2021 | -4.9% | -15.6% | +461.6% | |
| Q2 2021 | -35.7% | -32.9% | -31.1% | |
| Q1 2021 | +1.7% | +17.9% | +35.8% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro